The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats

Journal of Physiology and Pharmacology

Volumn 57, Issue 2, 2006, Pages 217-229

  Skuza, G ^a   Rogoz Z ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Amantadine; Forced swim; Memantine; Rats; Sigma agonists; Synergistic effect

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROSTEROID; PRAZOSIN; PROGESTERONE; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG MECHANISM; IMMOBILIZATION; LOCOMOTION; MALE; NONHUMAN; RAT;

ADRENERGIC ALPHA-ANTAGONISTS; AMANTADINE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETHYLENEDIAMINES; INDOLES; MALE; MEMANTINE; MOTOR ACTIVITY; PIPERAZINES; PRAZOSIN; PROGESTERONE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SIGMA; SPIRO COMPOUNDS; SULPIRIDE; SWIMMING;

EID: 33746040911     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-532.
2. Seth P, Fei YJ. Li HW, Huang W, Leibach FH, Ganapathy V. Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 1998; 70: 22-31.
3. Quirion R, Bowen W, Itzhak Y, Junien JM, Mussacchio JM, Rothman TP, Su TP, Tam S.W, Taylor DP. A proposal on the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85-86.
4. Itzhak Y, Kassim CO. Clorgyline displays high affinity for sigma binding sites in C57BL/6 mouse brain. Eur J Pharmacol 1990; 176: 107-108.
5. Largent BL, Wikstrom H, Gundlach AL., Snyder SH.: Structural determinants of σ-receptor affinity. Mol Pharmacol, 1987; 32: 772-784.
6. Sánchez C, Meier E. Behavioural profile of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 1997; 129: 197-205.
7. 1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996; 312: 267-271.
8. Skuza G., Rogóz Z.: Effect of combined treatment with selective sigma ligands and amantadine in the forced swimming test in rats. Pol J Pharmacol 2002; 54: 699-702.
9. Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of σ receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998; 61: 247-253.
10. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58: 721-734.
11. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
12. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; Suppl 3, S7-S14.
13. Maj J, Rogóż Z, Skuza G, Sowińska H. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur Neuropsychopharmacol 1992; 2: 37-41.
14. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994; 263: 1-7.
15. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185: 1-10.
16. Rogóż Z, Skuza G, Maj J, Danysz W. Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 2002; 42: 1024-1030.
17. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, De Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 1995; 280: 301-10.
18. 1 receptors in the mouse forebrain. J Neurosci Res 1996; 46: 734-743.
19. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-391.
20. Millan MJ. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. European Journal of Pharmacology 2004, 500: 371-384.
21. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269-284. Review.
22. Hayashi T, Maurice T, Su TP. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J Pharmacol Exp Ther 2000; 293: 788-798.
23. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002; 34: 399-410.
24. 1 receptor agonist. Eur J Pharmacol 1996; 306: 271-279.
25. Skuza G, Rogóż Z. Effect of 1,3-di-o-tolylguanidine (DTG), rimcazole and EMD 57445, the σ receptor ligands, in the forced swimming test. Pol J Pharmacol 1997; 49: 329-335.
26. Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA. Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001; 41: 138-149.
27. 1A receptor agonist OPC-14523. Neuropharmacology 2001; 41: 976-988.
28. 2 ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J Pharmacol Ex Ther 1997; 283: 1323-1332.
29. 2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol 2000; 11: 117-124.
30. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigmal receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev 2001; 37: 116-132.
31. Maurice T. Neurosteroids and sigmal receptors, biochemical and behavioral relevance. Pharmacopsychiatry 2004; 37 Suppl 3: S171-82.
32. Couture S, Debonnel G. Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands. Synapse 1998; 29: 62-71.
33. Gronier B, Debonnel G. Involvement of σ receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol 1999; 368: 183-196.
34. Gudelsky GA. Effects of σ receptor ligands on extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol 1995; 286: 223-228.
35. 1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological studies. Synapse 1999; 33: 129-140.
36. 1-adrenergic system. A behavioral study. Pol J Pharmacol 2001; 53: 547-550.
37. 1 receptor agonist. Behav Pharmacol 2002; 13: 537-543.
38. 3 receptors in rats. J Physiol Pharmacol 2003; 54: 257-270.
39. Skuza G, Rogóż Z. Sigmal receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol J Pharmacol 2003; 55: 1149-1152.
40. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci Lett 1993; 163: 129-131.
41. Martinez-Mota L, Contreras CM, Saavedra M. Progesterone reduces immobility in rats forced to swim. Arch Med Res 1999; 30:286-289.
42. Rogóż Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W. Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 2005; 56: 49-61.
43. Rogóż Z, Dziedzicka-Wasylewska M, Daniel WA, Wójcikowski J, Dudek D, Wróbel A, Ziȩba A. Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol 2004;56: 735-742.
44. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L, Rosenzcwaig S, Weizman A. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003; 18: 93-96.